Ufiprazole

Ufiprazole

SCHEMBL13645485

[2H]C([2H])([2H])Oc1ccc2[nH]c(SC([2H])([2H])c3ncc(C)c(OC([2H])([2H])[2H])c3C)nc2c1

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRS3 P32247 3/20 0.58
CYP2C9 P11712 11/20 0.43
CYP1A2 P05177 10/20 0.43
CYP3A4 P08684 10/20 0.43
CYP2C19 P33261 10/20 0.43
KMT2A Q03164 4/20 0.43
WDR5 P61964 3/20 0.43
HTT P42858 2/20 0.43
ATP1A1 P05023 2/20 0.43
ATP1B1 P05026 2/20 0.43
ATP1A3 P13637 2/20 0.43
ATP1B2 P14415 2/20 0.43
ATP4A P20648 2/20 0.43
ATP1A2 P50993 2/20 0.43
ATP4B P51164 2/20 0.43
ATP1B3 P54709 2/20 0.43
FXYD2 P54710 2/20 0.43
ATP1A4 Q13733 2/20 0.43
KDM4E B2RXH2 1/20 0.43
DDAH1 O94760 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ufiprazole SCHEMBL13645507 0.98 BRS3 (0.62) BRS3CYP2C9CYP1A2CYP3A4CYP2C19
Ufiprazole SCHEMBL3186458 0.91 BRS3 (0.71) BRS3CYP2C9CYP1A2CYP3A4CYP2C19
Ufiprazole SCHEMBL3170203 0.89 BRS3 (0.74) BRS3CYP2C9CYP1A2CYP3A4CYP2C19
Ufiprazole SCHEMBL3180530 0.88 BRS3 (0.76) BRS3CYP2C9CYP1A2CYP3A4CYP2C19
Ufiprazole SCHEMBL13645428 0.85 BRS3 (0.42) BRS3CYP2C9CYP1A2CYP3A4CYP2C19
Ufiprazole SCHEMBL13645476 0.84 BRS3 (0.45) BRS3CYP2C9CYP1A2CYP3A4CYP2C19
Ufiprazole SCHEMBL662986 0.82 BRS3 (0.84) BRS3CYP2C9CYP1A2CYP3A4CYP2C19
Ufiprazole SCHEMBL29455226 0.82 BRS3 (0.84) BRS3CYP2C9CYP1A2CYP3A4CYP2C19
Ufiprazole SCHEMBL31529606 0.81 BRS3 (0.82) BRS3CYP2C9CYP1A2CYP3A4CYP2C19
Ufiprazole SCHEMBL7929368 0.81 BRS3 (0.82) BRS3CYP2C9CYP1A2CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598273-B2 Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties AUSPEX PHARMACEUTICALS, INC (US) 2009-10-06 US disclosed
US-20090215831-A1 INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES AUSPEX PHARMACEUTICALS, INC. (US) 2009-08-27 US disclosed
US-20090209592-A1 INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES AUSPEX PHARMACEUTICALS, INC. (US) 2009-08-20 US disclosed
US-20070082929-A1 Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties AUSPEX PHARMACEUTICALS, INC. 2007-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209592-A1 INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES ATP4A, ATP6V1G1, ATP6V1E1 BRS3 2346/4885CYP2C9 2123/4885CYP1A2 1768/4885
US-20070082929-A1 Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties ATP4A, ATP6V1G1, ATP6V1E1 BRS3 2346/4885CYP2C9 2123/4885CYP1A2 1768/4885
US-20090215831-A1 INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES ATP4A, ATP6V1G1, ATP6V1E1 BRS3 2346/4885CYP2C9 2123/4885CYP1A2 1768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.